Cardiovascular sequelae of pneumonia

Current Opinion in Pulmonary Medicine

Volumn 25, Issue 3, 2019, Pages 257-262

  Brack, Markus C ^a   Lienau, Jasmin ^a   Kuebler, Wolfgang M ^b   Witzenrath, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BERLIN INSTITUTE OF HEALTH   (Germany)

Author keywords

Cardiovascular events; Pneumonia; Streptococcus pneumoniae

Indexed keywords

CALCIUM; TROPONIN; BIOLOGICAL MARKER;

ATHEROSCLEROTIC PLAQUE; BASIC RESEARCH; CARDIAC MUSCLE; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; HEART INJURY; HUMAN; LOWER RESPIRATORY TRACT INFECTION; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SCAR FORMATION; STREPTOCOCCUS PNEUMONIAE; ANIMAL; BLOOD; COMPLICATION; INFLAMMATION; MICROBIOLOGY; STREPTOCOCCUS PNEUMONIA;

ANIMALS; BIOMARKERS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; PNEUMONIA; PNEUMONIA, PNEUMOCOCCAL; TROPONIN;

EID: 85063924025     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000584     Document Type: Review

References (36)

1. Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012; 125:773–781.
2. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015; 313:264–274.
3. Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med 2011; 8:e1001048.
4. Corrales-Medina VF, Musher DM, Shachkina S, Chirinos JA. Acute pneumonia and the cardiovascular system. Lancet 2013; 381:496–505.
5. Violi F, Cangemi R, Falcone M, et al. Cardiovascular complications and short-term mortality risk in community-acquired pneumonia. Clin Infect Dis 2017; 64:1486–1493.
6. Mortensen EM, Kapoor WN, Chang CC, Fine MJ. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis 2003; 37:1617–1624.
7. Bornheimer R, Shea KM, Sato R, et al. Risk of exacerbation following pneumonia in adults with heart failure or chronic obstructive pulmonary disease. PLoS One 2017; 12:e0184877.
8. McDermott MM, Tian L, Wunderink RG, et al. Pulmonary hospitalizations and ischemic heart disease events in patients with peripheral artery disease. Vasc Med 2017; 22:218–224.
9. Eurich DT, Marrie TJ, Minhas-Sandhu JK, Majumdar SR. Risk of heart failure after community acquired pneumonia: prospective controlled study with 10 years of follow-up. BMJ 2017; 356:j413. The large prospective study shows that community-acquired pneumonia substantially increases the risk of heart failure across the age and severity range of cases over a 10-year period.
10. Blackburn R, Zhao H, Pebody R, et al. Laboratory-confirmed respiratory infections as predictors of hospital admission for myocardial infarction and stroke: time-series analysis of English data for 2004-2015. Clin Infect Dis 2018; 67:8–17.
11. Warren-Gash C, Blackburn R, Whitaker H, et al. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Respir J 2018; 51:pii: 1701794. A self-controlled case series based on national surveillance data reporting a pronounced triggering effect of both S. pneumoniae and influenza virus in AMI and stroke.
12. Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med 2018; 378:345–353. This work describes the association between laboratory-confirmed influenza infection and AMI. Further, the authors identified the first 7 days after detection of influenza as high-risk interval.
13. Chiang MH, Wu HH, Shih CJ, et al. Association between influenza vaccination and reduced risks of major adverse cardiovascular events in elderly patients. Am Heart J 2017; 193:1–7. A large, population-based case–control study demonstrating a protective effect of influenza vaccination against major CVEs in elderly patients.
14. Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013; 310:1711–1720.
15. Hebsur S, Vakil E, Oetgen WJ, et al. Influenza and coronary artery disease: exploring a clinical association with myocardial infarction and analyzing the utility of vaccination in prevention of myocardial infarction. Rev Cardiovasc Med 2014; 15:168–175.
16. Naghavi M, Wyde P, Litovsky S, et al. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Circulation 2003; 107:762–768.
17. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis 2010; 10:83–92.
18. Wang HE, Moore JX, Donnelly JP, et al. Risk of acute coronary heart disease after sepsis hospitalization in the REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort. Clin Infect Dis 2017; 65:29–36.
19. Cilli A, Cakin O, Aksoy E, et al. Acute cardiac events in severe community-acquired pneumonia: a multicenter study. Clin Respir J 2018; 12: 2212–2219.
20. Svanstrom H, Pasternak B, Hviid A. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. BMJ 2014; 349:g4930.
21. Antzelevitch C, Sun ZQ, Zhang ZQ, Yan GX. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 1996; 28:1836–1848.
22. Berni E, de Voogd H, Halcox JP, et al. Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study. BMJ Open 2017; 7:e013398.
23. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881–1890.
24. Polgreen LA, Riedle BN, Cavanaugh JE, et al. Estimated cardiac risk asso- ciated with macrolides and fluoroquinolones decreases substantially when adjusting for patient characteristics and comorbidities. J Am Heart Assoc 2018; 7:pii: e008074. This article highlights the importance of adjustment for risk factors when assessing the risk of macrolide antibiotics concerning CVEs, leading to a paradigm shift: The individual patient majorly determines the risk of macrolides for CVEs.
25. Lee YJ, Lee H, Park JS, et al. Cardiac troponin I as a prognostic factor in critically ill pneumonia patients in the absence of acute coronary syndrome. J Crit Care 2015; 30:390–394.
26. Vestjens SMT, Spoorenberg SMC, Rijkers GT, et al. High-sensitivity cardiac troponin T predicts mortality after hospitalization for community-acquired pneumonia. Respirology 2017; 22:1000–1006. This study shows that increased cardiac troponins on admission in patients hospitalized for CAP can serve as a prognostic biomarker for short-term and long-term mortality.
27. Corrales-Medina VF, Dwivedi G, Taljaard M, et al. Coronary artery calcium before and after hospitalization with pneumonia: the MESA study. PLoS One 2018; 13:e0191750. Assessing CAC in patients with high atherosclerotic cardiovascular disease (ASCVD) risk before and after pneumonia, and in comparable patients without pneumonia, the authors showed that pneumonia was followed by a larger increase in coronary atherosclerotic burden. This study provides important evidence that increased risk for CVEs after pneumonia is not solely due to a higher baseline burden of ASCVD in pneumonia patients.
28. Brown AO, Mann B, Gao G, et al. Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog 2014; 10:e1004383.
29. Gilley RP, Gonzalez-Juarbe N, Shenoy AT, et al. Infiltrated macrophages die of pneumolysin-mediated necroptosis following pneumococcal myocardial invasion. Infect Immun 2016; 84:1457–1469.
30. Shenoy AT, Beno SM, Brissac T, et al. Severity and properties of cardiac damage caused by Streptococcus pneumoniae are strain dependent. PLoS One 2018; 13:e0204032.
31. Shenoy AT, Brissac T, Gilley RP, et al. Streptococcus pneumoniae in the heart subvert the host response through biofilm-mediated resident macrophage killing. PLoS Pathog 2017; 13:e1006582. An experimental study highlighting that formation of biofilm and switch to an altered bacterial phenotype contribute to the pathogenesis of cardiac injury by S. pneumoniae in vivo.
32. Brissac T, Shenoy AT, Patterson LA, Orihuela CJ. Cell invasion and pyruvate oxidase derived H2O2 are critical for Streptococcus pneumoniae mediated cardiomyocyte killing. Infect Immun 2018; 86: e00569-17.
33. Reyes LF, Restrepo MI, Hinojosa CA, et al. Severe pneumococcal pneumonia causes acute cardiac toxicity and subsequent cardiac remodeling. Am J Respir Crit Care Med 2017; 196:609–620. This translational in-vivo study demonstrates cardiac injury with necroptosis and apoptosis in NHPs with pneumococcal pneumonia. Demonstrating cardiac scarring after antibiotic therapy, the authors also provide an explanation for increased frequency of CVEs after therapy of pneumonia.
34. Jaw JE, Tsuruta M, Oh Y, et al. Lung exposure to lipopolysaccharide causes atherosclerotic plaque destabilisation. Eur Respir J 2016; 48: 205–215.
35. Fuijkschot WW, Morrison MC, Zethof IPA, et al. LPS-induced systemic inflammation does not alter atherosclerotic plaque area or inflammation in APOE3*LEIDEN mice in the early phase up to 15 days. Shock 2018; 50:360–365.
36. Joshi R, Khandelwal B, Joshi D, Gupta OP. Chlamydophila pneumoniae infection and cardiovascular disease. N Am J Med Sci 2013; 5:169–181.